Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

6(66.7%)

Phase 1

3(33.3%)

9Total

Phase 2(6)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT00555646Phase 2Terminated

Topical PH-10 Aqueous Hydrogel and Photodynamic Therapy for Psoriasis

Role: lead

NCT02322086Phase 2Completed

A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10

Role: lead

NCT01760499Phase 1Completed

Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study

Role: collaborator

NCT00521053Phase 2Completed

Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma

Role: lead

NCT01247818Phase 2Completed

Randomized Study of PH-10 for Psoriasis

Role: lead

NCT00941278Phase 2Completed

An Efficacy and Safety Study of PH-10 Aqueous Hydrogel for the Treatment of Plaque Psoriasis

Role: lead

NCT00690807Phase 2Completed

A Phase 2 Study of PH-10 for the Treatment of Atopic Dermatitis

Role: lead

NCT00237354Phase 1Completed

PV-10 Chemoablation of Recurrent Breast Carcinoma

Role: lead

NCT00219843Phase 1Completed

Intralesional PV-10 Chemoablation of Metastatic Melanoma

Role: lead

All 9 trials loaded